Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -285.41% is 22% above its 5-year average of -364.51%, near the high end of its 5-year range (-3043.01%–-30.01%).
79.55% above its 12-month average of -1395.86%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -94.17%.
NET PROFIT MARGIN
-285.41%
NET PROFIT MARGIN AVG TTM
-1395.86%
NET PROFIT MARGIN AVG 3Y
-536.94%
NET PROFIT MARGIN AVG 5Y
-364.51%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+79.55%
CURRENT VS 3Y AVG
+46.85%
CURRENT VS 5Y AVG
+21.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-109673.08%
vs the sector median at left
Kymera Therapeutics, Inc.
Market Cap
$8.68B
Net Profit Margin
-285.41%
TTM Avg
-1395.86%
3Y Avg
-536.94%
5Y Avg
-364.51%
Market Cap
$8.79B
Net Profit Margin
-47.79%
TTM Avg
-8441.28%
3Y Avg
-4260.06%
5Y Avg
-2873.03%
Market Cap
$8.89B
Net Profit Margin
29.40%
TTM Avg
-109.74%
3Y Avg
-207.58%
5Y Avg
-253.39%
Market Cap
$8.91B
Net Profit Margin
-2.03%
TTM Avg
1.55%
3Y Avg
7.31%
5Y Avg
8.11%
Market Cap
$8.41B
Net Profit Margin
3.60%
TTM Avg
-1.75%
3Y Avg
-5.71%
5Y Avg
-20.27%
Market Cap
$9.04B
Net Profit Margin
-24.68%
TTM Avg
-51.58%
3Y Avg
-141.39%
5Y Avg
-94.26%
Market Cap
$9.18B
Net Profit Margin
-2.03%
TTM Avg
1.55%
3Y Avg
7.31%
5Y Avg
8.11%
Market Cap
$8.04B
Net Profit Margin
55.22%
TTM Avg
39.84%
3Y Avg
-1987.81%
5Y Avg
-32826.44%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.68B | -285.41% | -1395.86% | -536.94% | -364.51% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.79B | -47.79% | -8441.28% | -4260.06% | -2873.03% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.89B | 29.40% | -109.74% | -207.58% | -253.39% |
| Bruker Corporation (BRKRP)vs › | $8.91B | -2.03% | 1.55% | 7.31% | 8.11% |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | 3.60% | -1.75% | -5.71% | -20.27% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $9.04B | -24.68% | -51.58% | -141.39% | -94.26% |
| Bruker Corporation (BRKR)vs › | $9.18B | -2.03% | 1.55% | 7.31% | 8.11% |
| TG Therapeutics, Inc. (TGTX)vs › | $8.04B | 55.22% | 39.84% | -1987.81% | -32826.44% |
| Insulet Corp. (PODD)vs › | $9.37B | 12.29% | 14.66% | 10.46% | 7.35% |
| Vaxcyte, Inc. (PCVX)vs › | $9.42B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-891.3%
Net Profit Margin
-285.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -94.17% |
| 2026-03-31 | -201.47% |
| 2025-12-31 | -3043.01% |
| 2025-09-30 | -2973.05% |
| 2025-06-30 | -667.60% |
| 2025-03-31 | -296.75% |
| 2024-12-31 | -956.88% |
| 2024-09-30 | -1670.33% |
| 2024-06-30 | -163.98% |
| 2024-03-31 | -472.02% |
| 2023-12-31 | -30.01% |
| 2023-09-30 | -1118.17% |
| 2023-06-30 | -234.96% |
| 2023-03-31 | -432.37% |
| 2022-12-31 | -216.03% |
| 2022-09-30 | -450.24% |
| 2022-06-30 | -349.64% |
| 2022-03-31 | -381.25% |
| 2021-12-31 | -221.94% |
| 2021-09-30 | -140.55% |
| 2021-06-30 | -133.16% |
| 2021-03-31 | -69.91% |
| 2020-12-31 | -99.22% |
| 2020-09-30 | -54.95% |
| 2020-06-30 | -425.46% |
| 2020-03-31 | -318.90% |
| 2019-12-31 | -628.10% |
| 2019-09-30 | -1202.11% |
